Open-Angle Glaucoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：100頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Open-Angle Glaucoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H1 2014’, provides an overview of the Open-Angle Glaucoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H1 2014’, provides an overview of the Open-Angle Glaucoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Open-Angle Glaucoma Overview 9
Therapeutics Development 10
Pipeline Products for Open-Angle Glaucoma - Overview 10
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 11
Open-Angle Glaucoma - Therapeutics under Development by Companies 12
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 14
Open-Angle Glaucoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Open-Angle Glaucoma - Products under Development by Companies 19
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 20
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 21
Alcon, Inc. 21
F. Hoffmann-La Roche Ltd. 22
Bausch & Lomb Incorporated 23
Allergan, Inc. 24
Quark Pharmaceuticals, Inc. 25
Santen Pharmaceutical Co., Ltd. 26
Sylentis S.A. 27
Sun Pharmaceutical Industries Limited 28
Lexicon Pharmaceuticals, Inc. 29
Laboratoires Thea S.A. 30
Asahi Kasei Pharma Corp. 31
Inotek Pharmaceuticals Corporation 32
Otsuka Holdings Co., Ltd. 33
Amakem NV 34
High Point Pharmaceuticals, LLC 35
Open-Angle Glaucoma - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
tafluprost - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(tafluprost + timolol maleate) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tafluprost - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
latanoprostene bunod - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
latanoprost - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
latanoprost - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
trabodenoson - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PF-655 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SYL-040012 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
RO-5093151 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
latanoprost - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
aganepag isopropyl - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
simenepag isopropyl - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AL-54478 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AMA-0076 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATS-907 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DE-117 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
(latanoprost + dorzolamide) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LX-7101 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
HPP-851 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OPA-6566 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
brimonidine tartrate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ATS-8535 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule for Glaucoma - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ATS-907 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ATS-8535 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Open-Angle Glaucoma - Recent Pipeline Updates 82
Open-Angle Glaucoma - Dormant Projects 91
Open-Angle Glaucoma - Discontinued Products 92
Open-Angle Glaucoma - Product Development Milestones 93
Featured News & Press Releases 93
Jan 13, 2014: Forest Laboratories Pursues Additional Market Exclusivity to Extend Namenda Patent 93
Dec 12, 2012: Sucampo Pharma Receives FDA Approval Of sNDA For Rescula 93
May 01, 2012: Quark To Initiate Phase IIa Study Of PF-655 In Patients With Moderate And Advanced Open-Angle Glaucoma 93
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 94
Feb 13, 2012: FDA Approves Merck's ZIOPTAN For Treatment Of Intraocular Pressure In Glaucoma Patients 95
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 96
Sep 26, 2011: Clermont Reports Positive Phase III Results For Non-Preserved Latanoprost To Treat Glaucoma 96
May 06, 2010: R-Tech Ueno's Sanda Factory Gets U.S. Nod for Manufacture of Rescula Eye Drops. 96
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 97
Mar 04, 2010: Frost & Sullivan Recognizes Timoptic as Best Brand Name Beta Blocker for Glaucoma 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100
List of Tables
Number of Products under Development for Open-Angle Glaucoma, H1 2014 10
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Comparative Analysis by Unknown Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Open-Angle Glaucoma - Pipeline by Alcon, Inc., H1 2014 21
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 22
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2014 23
Open-Angle Glaucoma - Pipeline by Allergan, Inc., H1 2014 24
Open-Angle Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 25
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 26
Open-Angle Glaucoma - Pipeline by Sylentis S.A., H1 2014 27
Open-Angle Glaucoma - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 28
Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc.., H1 2014 29
Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H1 2014 30
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2014 31
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2014 32
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 33
Open-Angle Glaucoma - Pipeline by Amakem NV, H1 2014 34
Open-Angle Glaucoma - Pipeline by High Point Pharmaceuticals, LLC., H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H1 2014 82
Open-Angle Glaucoma - Dormant Projects, H1 2014 91
Open-Angle Glaucoma - Discontinued Products, H1 2014 92
List of Figures
Number of Products under Development for Open-Angle Glaucoma, H1 2014 10
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Open-Angle Glaucoma Overview 9
Therapeutics Development 10
Pipeline Products for Open-Angle Glaucoma - Overview 10
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 11
Open-Angle Glaucoma - Therapeutics under Development by Companies 12
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 14
Open-Angle Glaucoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Open-Angle Glaucoma - Products under Development by Companies 19
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 20
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 21
Alcon, Inc. 21
F. Hoffmann-La Roche Ltd. 22
Bausch & Lomb Incorporated 23
Allergan, Inc. 24
Quark Pharmaceuticals, Inc. 25
Santen Pharmaceutical Co., Ltd. 26
Sylentis S.A. 27
Sun Pharmaceutical Industries Limited 28
Lexicon Pharmaceuticals, Inc. 29
Laboratoires Thea S.A. 30
Asahi Kasei Pharma Corp. 31
Inotek Pharmaceuticals Corporation 32
Otsuka Holdings Co., Ltd. 33
Amakem NV 34
High Point Pharmaceuticals, LLC 35
Open-Angle Glaucoma - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
tafluprost - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(tafluprost + timolol maleate) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tafluprost - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
latanoprostene bunod - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
latanoprost - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
latanoprost - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
trabodenoson - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PF-655 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SYL-040012 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
RO-5093151 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
latanoprost - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
aganepag isopropyl - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
simenepag isopropyl - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AL-54478 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AMA-0076 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATS-907 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DE-117 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
(latanoprost + dorzolamide) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LX-7101 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
HPP-851 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OPA-6566 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
brimonidine tartrate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ATS-8535 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule for Glaucoma - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ATS-907 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ATS-8535 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Open-Angle Glaucoma - Recent Pipeline Updates 82
Open-Angle Glaucoma - Dormant Projects 91
Open-Angle Glaucoma - Discontinued Products 92
Open-Angle Glaucoma - Product Development Milestones 93
Featured News & Press Releases 93
Jan 13, 2014: Forest Laboratories Pursues Additional Market Exclusivity to Extend Namenda Patent 93
Dec 12, 2012: Sucampo Pharma Receives FDA Approval Of sNDA For Rescula 93
May 01, 2012: Quark To Initiate Phase IIa Study Of PF-655 In Patients With Moderate And Advanced Open-Angle Glaucoma 93
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 94
Feb 13, 2012: FDA Approves Merck's ZIOPTAN For Treatment Of Intraocular Pressure In Glaucoma Patients 95
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 96
Sep 26, 2011: Clermont Reports Positive Phase III Results For Non-Preserved Latanoprost To Treat Glaucoma 96
May 06, 2010: R-Tech Ueno's Sanda Factory Gets U.S. Nod for Manufacture of Rescula Eye Drops. 96
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 97
Mar 04, 2010: Frost & Sullivan Recognizes Timoptic as Best Brand Name Beta Blocker for Glaucoma 98
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100
List of Tables
Number of Products under Development for Open-Angle Glaucoma, H1 2014 10
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Comparative Analysis by Unknown Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Open-Angle Glaucoma - Pipeline by Alcon, Inc., H1 2014 21
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 22
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2014 23
Open-Angle Glaucoma - Pipeline by Allergan, Inc., H1 2014 24
Open-Angle Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 25
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 26
Open-Angle Glaucoma - Pipeline by Sylentis S.A., H1 2014 27
Open-Angle Glaucoma - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 28
Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc.., H1 2014 29
Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H1 2014 30
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2014 31
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2014 32
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 33
Open-Angle Glaucoma - Pipeline by Amakem NV, H1 2014 34
Open-Angle Glaucoma - Pipeline by High Point Pharmaceuticals, LLC., H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H1 2014 82
Open-Angle Glaucoma - Dormant Projects, H1 2014 91
Open-Angle Glaucoma - Discontinued Products, H1 2014 92
List of Figures
Number of Products under Development for Open-Angle Glaucoma, H1 2014 10
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 36
Assessment by Combination Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47
